The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Meta‐analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes
Open accessAbstract
Aims: Since 2002, there have been five major outcome trials of statins reporting findings from more than 47 000 subjects. As individual trial results differed, we performed a meta‐analysis to ascertain the effectiveness and safety of statins overall and in subgroups. The aim of the study was to estimate the effect of statins on major coronary events and strokes, all‐cause mortality and noncardiovascular mortality, and in different subgroups. Methods: PubMed was searched for trials published in English. Randomized placebo‐controlled statin trials with an average follow up of at least 3 years and at least 100 major coronary events were included. For each trial, the statin used, number and type of subjects, proportion of women, mean age and follow up, baseline and change in lipid profile, cardiovascular and non‐cardiovascular outcomes were recorded. Results: Ten trials involving 79 494 subjects were included in the meta‐analysis. Due to heterogeneity, ALLHAT‐LLT was excluded from some analyses. Statin therapy reduced major coronary events by 27% (95%CI 23, 30%), stroke by 18% (95%CI 10, 25%) and all‐cause mortality by 15% (95%CI 8, 21%). There was a 4% (95%CI −10, 3%) nonsignificant reduction in noncardiovascular mortality. The reduction in major coronary events is independent of gender and presence of hypertension or diabetes. The risk reduction was greater in smokers (P < 0.05). Coronary events were reduced by 23% (95%CI 18, 29%) in pravastatin trials and 29% (95%CI 25, 33%) in five trials using other statins. Pravastatin reduced strokes by 12% (95%CI 1, 21%) whilst other statins reduced strokes by 24% (95%CI 16, 32%) (P = 0.04). Conclusions: Statins reduce coronary events, strokes and all‐cause mortality without increasing noncoronary mortality. The benefits accrue in men and women, hypertensives and normotensives, diabetics and nondiabetics, and particularly in smokers. Pravastatin appears to have less impact on strokes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Burt, V. L., Whelton, P., Roccella, E. J., Brown, C., Cutler, J. A., Higgins, M., Horan, M. J., & Labarthe, D. (1995) · Hypertension · doi:10.1161/01.hyp.25.3.305 · Cited by 2,998
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Cardiovascular disease risk profiles
Anderson, K. M., Odell, P. M., Wilson, P. W. F., & Kannel, W. B. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90861-b · Cited by 2,163
Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., Hsia, J., Hulley, S., Herd, A., Khan, S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,930
Prescribing Personalized Nutrition for Cardiovascular Health: Are We Ready?
Juma, S., Imrhan, V., Vijayagopal, P., & Prasad, C. (2014) · Lifestyle Genomics · doi:10.1159/000370213 · Cited by 1,891
The Handbook of Research Synthesis.
Light, R. J., Cooper, H., & Hedges, L. V. (1994) · Journal of the American Statistical Association · doi:10.2307/2291021 · Cited by 1,868
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2998 · Cited by 1,331
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
(1997) · New England Journal of Medicine · doi:10.1056/nejm199701163360301 · Cited by 970
(1995) · The Lancet · doi:10.1016/s0140-6736(95)92836-7 · Cited by 856
Jukema, J. W., Bruschke, A. V. G., van Boven, A. J., Reiber, J. H. C., Bal, E. T., Zwinderman, A. H., Jansen, H., Boerma, G. J. M., van Rappard, F. M., & Lie, K. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 842
Serruys, P. W. J. C. (2002) · JAMA · doi:10.1001/jama.287.24.3215 · Cited by 719
Athyros, V. G., Papageorgiou, A. A., Mercouris, B. R., Athyrou, V. V., Symeonidis, A. N., Basayannis, E. O., Demitriadis, D. S., & Kontopoulos, A. G. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000787 · Cited by 533
Pedersen, T. R., Kjekshus, J., Pyörälä, K., Olsson, A. G., Cook, T. J., Musliner, T. A., Tobert, J. A., & Haghfelt, T. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00904-1 · Cited by 466
Assmann, G., Schulte, H., & von Eckardstein, A. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00159-2 · Cited by 447
Coronary Heart Disease in Patients with Diabetes
Haffner, S. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004063421408 · Cited by 410
Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., Keech, A., Packard, C., Simes, J., Byington, R., et al. (2000) · Circulation · doi:10.1161/01.cir.102.16.1893 · Cited by 388
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530250059028 · Cited by 380
Serruys, P. (1999) · European Heart Journal · doi:10.1053/euhj.1998.1150 · Cited by 259
Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial
Liem, A. H., Boven, A. J. V., Veeger, N. J. G. M., Withagen, A. J. A. M., de Medina, R. M. R., Tijssen, J. G. P., & van Veldhuisen, D. J. (2002) · European Heart Journal · doi:10.1053/euhj.2002.3291 · Cited by 126
Grady, D. G., Herrington, D. M., Bittner, V., Blumenthal, R. S., Davidson, M. H., Hlatky, M. A., Hsia, J. A., Hulley, S. B., Herd, A. J., Khan, S. S., et al. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200210000-00020 · Cited by 124
Deaths due to Accidents and Violence in Two Recent Trials of Cholesterol-Lowering Drugs
Wysowski, D. K. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.10.2169 · Cited by 88
Gauging the Impact of Statins Using Number Needed to Treat
Kumana, C. R., Cheung, B. M., & Lauder, I. J. (1999) · JAMA · doi:10.1001/jama.282.20.1899 · Cited by 76
Self-citationShould decisions on treatment be based on absolute benefit rather than absolute risk?
Cheung, B. M. Y., & Kumana, C. R. (2001) · PubMed · Cited by 9
Self-citation
Research works printed but not linked: 3
- 10.1016/S0140-6736(05)71806-7 · doi:10.1016/s0140-6736(05)71806-7
- 10.1136/bmj.326.7391.689 · doi:10.1136/bmj.326.7391.689
- 10.1136/bmj.327.7405.51 · doi:10.1136/bmj.327.7405.51
Cited by
Bowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922
“Evidence from randomized trials of pharmaceutical interventions to lower LDL-c concentrations (such as statins (Pedersen et al., 1994; Cheung et al., 2004)), and from Mendelian randomization (LinselNitschke et al., 2008; Do et al., 2013) suggests that this association is reflective of a causal…”
BackgroundAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Austin, P. C., & Mamdani, M. M. (2006) · Statistics in Medicine · doi:10.1002/sim.2328 · Cited by 560
Metadata
- Authors
- Cheung, B. M. Y., Lauder, I. J., Lau, C., & Kumana, C. R.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2004-03-23
- Volume
- 57
- Issue
- 5
- Pages
- 640-651
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2032568924
- Cited by
- 304
- References
- 41
- FWCI
- 26.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.